Azitra Inc Dossier
Qualitative Analysis
Business overview
Azitra, Inc. (NYSE American: AZTR) is an early-stage, clinical-biopharmaceutical company specializing in precision dermatology. The company leverages synthetic biology, genetic engineering, and artificial intelligence to develop innovative therapies using engineered proteins and topical live biotherapeutic products. Azitra's proprietary platform includes a microbial library of approximately 1,500 unique bacterial strains, primarily focusing on genetically engineered strains of Staphylococcus epidermidis to treat serious skin diseases.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Developing ATR-COSF, a recombinant filaggrin protein, as a cosmetic ingredient to address skin barrier dysfunction.
Expected impact: Provides a shorter, less costly regulatory pathway to commercialization and opens up a multi-billion dollar skincare market.
Utilizing in-licensed microbial genetic engineering technologies from the Fred Hutchinson Cancer Center to produce high-value recombinant proteins, such as mRNA-related assembly proteins (TEV Protease and T7 RNA Polymerase).
Expected impact: Targets the $1 billion polymerases and proteases market, creating parallel non-therapeutic revenue streams.
Pausing further patient enrollment in the ATR-12 Phase 1b clinical trial for Netherton syndrome to conserve capital and redirect funds toward the near-term ATR-COSF cosmetic program.
Expected impact: Reduces cash burn rate and optimizes resource allocation toward faster-to-market assets.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Added as a key clinical site for the ongoing Phase 1/2 clinical trial of ATR-04 for EGFRi-associated skin rash.
Terms: Not disclosed.
In-licensed advanced microbial genetic engineering technologies, including minicircle plasmids, to enable the production of high-value recombinant proteins for biotech applications.
Terms: Not disclosed.
Collaborating to screen Azitra's proprietary library of bacterial strains for novel, drug-like peptides and proteins to address skin health and eczema.
Terms: Joint Development Agreement entered in December 2019; potential for future milestones and royalties.